Filip Krag Knop

Filip Krag Knop

Clinical Professor

Member of:

  • Internal Medicine: Endocrinology


  1. Published

    Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus

    Aaboe, K., Knop, Filip Krag, Vilsbøll, T., Deacon, Carolyn F., Holst, Jens Juul, Madsbad, S. & Krarup, T. M., 1 Apr 2010, In: Diabetes, Obesity and Metabolism. 12, 4, p. 323-33 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Published

    Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose- and non-glucose-induced insulin secretion in patients with type 2 diabetes mellitus

    Aaboe, K., Knop, Filip Krag, Vilsbøll, Tina, Deacon, Carolyn F., Holst, Jens Juul, Madsbad, Sten & Krarup, T., 2010, In: Diabetes, Obesity and Metabolism. 12, 4, p. 323-333 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?

    Asmar, M., Bache, M., Knop, Filip Krag, Madsbad, Sten & Holst, Jens Juul, 1 May 2010, In: The Journal of clinical endocrinology and metabolism. 95, 5, p. 2367-75 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

    Christensen, M. & Knop, Filip Krag, 1 Apr 2010, In: Current Diabetes Reports. 10, 2, p. 124-32 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes

    Christensen, M., Knop, Filip Krag, Vilsbøll, Tina, Aaboe, K., Holst, Jens Juul, Madsbad, Sten & Krarup, T., 9 Aug 2010, In: Regulatory Peptides. 163, 1-3, p. 96-101 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects

    Hansen, K. B., Vilsbøll, Tina, Bagger, J. I., Holst, Jens Juul & Knop, Filip Krag, 1 Jul 2010, In: The Journal of clinical endocrinology and metabolism. 95, 7, p. 3309-17 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review

    Hansen, K. B., Vilsbøll, Tina & Knop, Filip Krag, 1 Jan 2010, In: Diabetes, Metabolic Syndrome and Obesity. 3, p. 155-63 9 p.

    Research output: Contribution to journalReviewResearchpeer-review

  8. Published

    Incretin-based therapy and type 2 diabetes

    Hare, K. J. & Knop, Filip Krag, 1 Jan 2010, In: Vitamins and Hormones. 84, p. 389-413 25 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes

    Hare, K. J., Vilsbøll, Tina, Holst, Jens Juul & Knop, Filip Krag, 1 Apr 2010, In: American Journal of Physiology: Endocrinology and Metabolism. 298, 4, p. E832-7 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

    Hare, K. J., Vilsbøll, Tina, Asmar, M., Deacon, Carolyn F., Knop, Filip Krag & Holst, Jens Juul, 1 Jul 2010, In: Diabetes. 59, 7, p. 1765-70 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 Next

ID: 40100368